OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital.

The company's lead candidate, CD24Fc, is in a Phase II study to prevent graft versus host disease (GvHD). CD24Fc is a recombinant fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain...